Literature DB >> 9314102

Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses.

A Reles1, U Wein, W Lichtenegger.   

Abstract

OBJECTIVE: This investigation was undertaken to evaluate the predictive value of the blood flow velocity as measured by transvaginal color Doppler sonography (CDS) and conventional sonographic criteria in the preoperative assessment of ovarian tumors.
METHODS: 98 patients who were admitted for surgery with a suspicion of an adnexal mass (69 benign tumors, 4 borderline tumors, and 25 malignant tumors) were prospectively studied with transvaginal sonography (TVS) and CDS. Pulsatility index of blood flow velocity waveforms was evaluated by CDS and compared with established sonographic criteria for discriminating between benign and malignant ovarian tumors.
RESULTS: TVS had a sensitivity of 91% and a specificity of 84% in detecting malignant ovarian tumors compared with CDS with a sensitivity of 90% and a specificity of 74%, using 1.1 as a cut-off value for the pulsatility index. The specificity of CDS was higher in postmenopausal (88%) than in premenopausal (63%) patients. Using TVS and CDS combined, the sensitivity and specificity of diagnosing malignant ovarian tumors could be increased to 95% and 86%.
CONCLUSION: In premenopausal patients, TVS is clearly a more sensitive and more specific technique than CDS in correctly identifying benign and malignant ovarian tumors, whereas in postmenopausal patients, CDS gives useful additional information concerning blood vessel resistance. If CDS is used as an additional technique to TVS, it can increase the sensitivity and specificity of TVS in discriminating between benign and malignant ovarian tumors.

Entities:  

Mesh:

Year:  1997        PMID: 9314102     DOI: 10.1002/(sici)1097-0096(199706)25:5<217::aid-jcu1>3.0.co;2-g

Source DB:  PubMed          Journal:  J Clin Ultrasound        ISSN: 0091-2751            Impact factor:   0.910


  7 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Evaluation of whether the ultrasonographic onion skin sign is specific for the diagnosis of an appendiceal mucocele.

Authors:  Toru Kameda; Fukiko Kawai; Nobuyuki Taniguchi; Kiyoka Omoto; Yasuyuki Kobori; Kazukiyo Arakawa
Journal:  J Med Ultrason (2001)       Date:  2014-03-06       Impact factor: 1.314

3.  Diagnostic value of contrast-enhanced ultrasonography in the characterization of ovarian tumors().

Authors:  L M Sconfienza; N Perrone; A Delnevo; F Lacelli; C Murolo; N Gandolfo; G Serafini
Journal:  J Ultrasound       Date:  2009-10-13

4.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

5.  Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements.

Authors:  Arthur C Fleischer; Andrej Lyshchik; Makiko Hirari; Ryan D Moore; Richard G Abramson; David A Fishman
Journal:  J Oncol       Date:  2012-04-26       Impact factor: 4.375

Review 6.  PET/CT and cross sectional imaging of gynecologic malignancy.

Authors:  Revathy B Iyer; Aparna Balachandran; Catherine E Devine
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

7.  Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.

Authors:  A Coumbos; J Sehouli; R Chekerov; D Schaedel; G Oskay-Oezcelik; W Lichtenegger; W Kuehn
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.